February 29, 2012
OSLO, NorwayThe Aker BioMarine Science Advisory Board (SAB) met with Aker BioMarine's (AKBM) research and development scientists for the second meeting since the board was formed last fall. This meeting had a particular focus on joint health and inflammation.
Together, the board members and Aker scientists developed the basis for a planned clinical study with Superba krill oil and powder compositions to further substantiate krill's benefits in this area. The issues surrounding the development of the study protocol were discussed in detail to establish a foundation for a successful project outcome. The study will start later this year.
Further, scientific presentations were given by all the SAB members providing updates and background on issues important for research involving krill products and aspects of sustainability.
Particularly, Steve Nicol, Ph.D.,an expert in Antarctic sustainability, gave an update on the current status for the krill biomass in the Southern Ocean.
"Krill harvesting will always be subject to scrutiny," Nicol, said, but he further pointed out, "there is no indication that the current level of krill catch has had any impact on the performance of krill predators in the area where the krill is harvested, and the impacts of krill fishing are being monitored closely by scientists, conservationists, governments and industry alike."
Di Marzo, Ph.D., and Banni, Ph.D., presented the latest updates within the endocannabinoid field, followed by Dr. Calder, who gave an update on omega-3 fatty acids and their role in inflammation. Dr .Harris gave an update on the latest findings within omega-3 index research.
The next SAB meeting will be held in September 2012.
You May Also Like